Hyperbaric oxygen therapy for central retinal artery occlusion: experience in Hong Kong

Lai Ting Yip, S. Au, C. Ko
{"title":"Hyperbaric oxygen therapy for central retinal artery occlusion: experience in Hong Kong","authors":"Lai Ting Yip, S. Au, C. Ko","doi":"10.12809/hkjo-v24n2-281","DOIUrl":null,"url":null,"abstract":"Objective: To review medical records of patients who underwent hyperbaric oxygen therapy (HBOT) for central retinal artery occlusion (CRAO).Methods: Medical records of patients who underwent HBOT for CRAO between November 2018 and December 2019 were reviewed. The first emergency HBOT was at 2.8 atmosphere absolute for 90 minutes with staged decompression. Subsequent sessions were at 2.4 atmosphere absolute twice daily or daily. Patients were followed up daily at the eye clinic. HBOT lasted for 5 days or 10 treatment sessions if there was visual improvement on day 3. Treatments were discontinued if patients had no visual improvement or were unable to tolerate the treatment or experienced major adverse effects, or when the patient was confirmed to not have CRAO.Results: Of 31 patients who underwent HBOT, 25 with CRAO (17 men, 8 women; aged 44 to 89 years) were included. Mean onset-to-door time was 3.3±4.2 hours, and mean onset-to-HBOT time was 13.3±7.4 hours. Mean number of HBOT sessions was 7.9±2.7. Mean change in visual acuity (VA) was -0.43 LogMAR (p=0.003). At the end of treatment, 84% had VA of 0.1 (1.0 logMAR) or worse and 64% had VA of finger counting (1.7 logMAR) or worse. No factors were associated with VA improvement including age, onset-to-door time, onset-to-HBOT time, number of HBOT sessions, or pre-HBOT VA.\nConclusion: HBOT for CRAO shows promising visual outcomes. It is important to be aware of the systemic complication of CRAO and provide timely systemic cardiovascular work up for CRAO patients.","PeriodicalId":90844,"journal":{"name":"Hong Kong journal of ophthalmology : the official publication of the College of Ophthalmologists of Hong Kong = Xianggang yan ke xue kan : Xianggang yan ke yi xue yuan","volume":" ","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2020-12-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"6","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Hong Kong journal of ophthalmology : the official publication of the College of Ophthalmologists of Hong Kong = Xianggang yan ke xue kan : Xianggang yan ke yi xue yuan","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.12809/hkjo-v24n2-281","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 6

Abstract

Objective: To review medical records of patients who underwent hyperbaric oxygen therapy (HBOT) for central retinal artery occlusion (CRAO).Methods: Medical records of patients who underwent HBOT for CRAO between November 2018 and December 2019 were reviewed. The first emergency HBOT was at 2.8 atmosphere absolute for 90 minutes with staged decompression. Subsequent sessions were at 2.4 atmosphere absolute twice daily or daily. Patients were followed up daily at the eye clinic. HBOT lasted for 5 days or 10 treatment sessions if there was visual improvement on day 3. Treatments were discontinued if patients had no visual improvement or were unable to tolerate the treatment or experienced major adverse effects, or when the patient was confirmed to not have CRAO.Results: Of 31 patients who underwent HBOT, 25 with CRAO (17 men, 8 women; aged 44 to 89 years) were included. Mean onset-to-door time was 3.3±4.2 hours, and mean onset-to-HBOT time was 13.3±7.4 hours. Mean number of HBOT sessions was 7.9±2.7. Mean change in visual acuity (VA) was -0.43 LogMAR (p=0.003). At the end of treatment, 84% had VA of 0.1 (1.0 logMAR) or worse and 64% had VA of finger counting (1.7 logMAR) or worse. No factors were associated with VA improvement including age, onset-to-door time, onset-to-HBOT time, number of HBOT sessions, or pre-HBOT VA. Conclusion: HBOT for CRAO shows promising visual outcomes. It is important to be aware of the systemic complication of CRAO and provide timely systemic cardiovascular work up for CRAO patients.
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
高压氧治疗视网膜中央动脉阻塞:香港经验
目的:回顾因视网膜中央动脉闭塞(CRAO)接受高压氧治疗(HBOT)的患者的医疗记录。方法:回顾2018年11月至2019年12月期间因CRAO接受HBOT治疗的患者的病历。第一次紧急HBOT在2.8绝对大气压下持续90分钟,分阶段减压。随后的会议每天或每天两次在2.4个绝对大气压下进行。患者每天在眼科诊所接受随访。HBOT持续5天,如果第3天视觉改善,则持续10次治疗。如果患者视力没有改善,或无法耐受治疗或出现严重不良反应,或患者被证实没有CRAO,则停止治疗。结果:在31名接受HBOT的患者中,25名CRAO患者(17名男性,8名女性;年龄44至89岁)被纳入。平均上门时间为3.3±4.2小时,平均HBOT时间为13.3±7.4小时。HBOT的平均次数为7.9±2.7次。视力(VA)的平均变化为-0.43LogMAR(p=0.003)。治疗结束时,84%的患者视力为0.1(1.0logMAR)或更差,64%的患者手指计数视力为1.7logMAR或更差。没有与VA改善相关的因素,包括年龄、发病到门时间、发病到HBOT时间、HBOT疗程次数或HBOT前VA。结论:CRAO的HBOT显示出良好的视觉效果。重要的是要意识到CRAO的全身并发症,并为CRAO患者提供及时的全身心血管检查。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
自引率
0.00%
发文量
0
期刊最新文献
Guided tour to the hyperbaric oxygen therapy center in Hong Kong Amblyopia management Expert opinions on benefit-risk profile and clinical use of brolucizumab AcuFocus IC-8 intraocular lens for myopic patients with cataract: a retrospective study Artificial intelligence to detect referable diabetic retinopathy in a Chinese population in Hong Kong
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1